Metagenomi posts Q2 2026 loss, cash at $120.7M
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Metagenomi Therapeutics, Inc. reported second quarter 2026 results and business updates, highlighting progress on its lead in vivo genome editing program MGX-001 for hemophilia A. IND-enabling studies are expected to be completed by the end of the third quarter of 2026, with an IND filing planned for the fourth quarter of 2026 and, subject to regulatory clearance, clinical trial initiation in 2027.
Cash, cash equivalents and available-for-sale marketable securities totaled $120.7 million as of June 30, 2026, and the company anticipates this cash runway will support operations through the fourth quarter of 2027. For the quarter, collaboration revenue was $(0.257) million, R&D expenses were $22.5 million, G&A expenses were $6.0 million, and net loss was $27.5 million, or $(0.73) per share.
Second quarter updates also noted that two Metagenomi posters, including one with extensive non-human primate data supporting MGX-001, received Top Poster Awards at the 2026 ISTH Congress. The company continues to evaluate additional disease indications for its large gene integration system for protein replacement via gene insertion.
Positive
- $120.7 million in cash, cash equivalents and marketable securities as of June 30, 2026, with runway expected to support operations through 4Q 2027.
- Operating expenses showed discipline: G&A for Q2 2026 declined to $6.0 million from $7.0 million in the prior-year quarter, and year-to-date R&D and G&A were both lower than 2025.
- Lead program MGX-001 remains on track, with IND-enabling studies expected to complete by end of Q3 2026 and an IND filing planned for Q4 2026, targeting clinical trials in 2027.
Negative
- Collaboration revenue declined sharply, from $8.5 million in Q2 2025 to $(0.3) million in Q2 2026, and from $12.6 million to $1.0 million for the six-month periods.
- Net loss increased to $27.5 million in Q2 2026 from $19.9 million a year earlier, and to $50.5 million for the first half of 2026 compared with $44.9 million in 2025.
- The cash, cash equivalents and marketable securities balance decreased from $160.8 million at December 31, 2025 to $120.7 million at June 30, 2026, reflecting ongoing operating losses.
Filing Explained
As of June 30, cash plus securities were $120.7 million, down from $160,799 thousand at December 31, 2025.
The August 10, 2026 8-K furnishes the company’s completed second-quarter results and business updates. Its structural consequence is updated liquidity information: cash, cash equivalents, and available-for-sale marketable securities were
Form 8-K reports specified material events, and Item 2.02 covers results of operations and financial condition. The earnings release is furnished with the 8-K and is not deemed filed for Section 18 purposes.
The balance-sheet table reports
8-K Event Classification
Key Figures
Key Terms
investigational new drug (IND) application regulatory
available-for-sale marketable securities financial
hemophilia A medical
in vivo genome editing technical
forward-looking statements regulatory
Earnings Snapshot
Company anticipates its cash, cash equivalents and marketable securities will support operations through the fourth quarter of 2027.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What were Metagenomi Therapeutics (MGX) cash and runway as of June 30, 2026?
How did Metagenomi Therapeutics (MGX) perform financially in Q2 2026?
What progress did Metagenomi Therapeutics (MGX) report on MGX-001?
How did Metagenomi Therapeutics (MGX) R&D and G&A expenses change in Q2 2026?
What were Metagenomi Therapeutics (MGX) total assets and equity at June 30, 2026?
How did collaboration revenue for Metagenomi Therapeutics (MGX) change year over year?
AI-generated analysis. How Rhea-AI works. Not financial advice.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): |
(Exact name of Registrant as Specified in Its Charter)
(State or Other Jurisdiction |
(Commission File Number) |
(IRS Employer |
||
|
|
|
|
|
|
||||
|
||||
(Address of Principal Executive Offices) |
|
(Zip Code) |
||
Registrant’s Telephone Number, Including Area Code: |
|
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Securities registered pursuant to Section 12(b) of the Act:
|
|
Trading |
|
|
|
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
Item 2.02 Results of Operations and Financial Condition.
On August 10, 2026, Metagenomi Therapeutics, Inc. (the “Company”) announced its financial results for the quarter ended June 30, 2026 and additional business updates. A copy of the press release in connection with the announcement is being furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.
The information in this Item 2.02 (including Exhibit 99.1 attached hereto) is intended to be furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended (the “Securities Act”), except as expressly set forth by specific reference in such filing.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits
Exhibit No. |
|
Description |
99.1 |
|
Earnings Press Release Issued by Metagenomi Therapeutics, Inc. on August 10, 2026 |
104 |
|
Cover Page Interactive Data File (embedded within the Inline XBRL document) |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
|
Metagenomi Therapeutics, Inc. |
|
|
|
|
Date: |
August 10, 2026 |
By: |
/s/ Jian Irish |
|
|
|
Jian Irish, Ph.D., M.B.A. |
Exhibit 99.1
Metagenomi Therapeutics Reports Business Updates and Second Quarter 2026 Financial Results
Remains on track to submit investigational new drug (IND) application in 4Q 2026 for the global clinical program of MGX-001 for the treatment of hemophilia A
$120.7 million in cash, cash equivalents, and available-for-sale marketable securities as of June 30, 2026, with runway anticipated to support operations through 4Q 2027
EMERYVILLE, Calif., August 10, 2026 (GLOBE NEWSWIRE) -- Metagenomi Therapeutics, Inc. (Nasdaq: MGX) (the “Company”), an in vivo genome editing company capitalizing on its proprietary technologies to create curative genetic medicines for patients, today reported financial results for the second quarter ended June 30, 2026, and provided business updates.
“During the second quarter, we continued to execute against our strategic priorities while advancing toward our planned regulatory submissions for our MGX-001 program in hemophilia A later this year,” said Jian Irish, Ph.D., M.B.A., President and Chief Executive Officer of Metagenomi Therapeutics. “As we prepare to enter the clinic, we are engaging with leading hemophilia investigators and key opinion leaders to establish a strong foundation for our first-in-human study. We believe our differentiated genome editing platform positions us to pursue durable genetic medicines, and we remain focused on disciplined execution as we move toward our upcoming regulatory and clinical milestones.”
Second Quarter 2026 Updates
MGX-001 - Hemophilia A Program
MGX-001 - Large Gene Integration System for Protein Replacement via Gene Insertion
Second Quarter 2026 Financial Results
Cash Position: Cash, cash equivalents, and available-for-sale marketable securities were $120.7 million as of June 30, 2026.
R&D Expenses: Research and development (R&D) expenses were $22.5 million for the quarter ended June 30, 2026, compared to $22.5 million for the comparable period in 2025.
G&A Expenses: General and administrative (G&A) expenses were $6.0 million for the quarter ended June 30, 2026, compared to $7.0 million for the comparable period in 2025.
About Metagenomi Therapeutics
Metagenomi Therapeutics, Inc. is an in vivo genome editing company capitalizing on its proprietary technologies to create curative genetic medicines for patients. The Company was founded on the science of metagenomics, the study of genetic materials recovered from the natural environment, to discover and develop a suite of novel CRISPR gene-editing tools potentially capable of correcting any type of genetic mutation found anywhere in the human genome. The Company focuses on high value programs in disease indications with well-understood biology and clearly defined clinical development and regulatory pathways. Going forward, the Company intends to continue to expand its pipeline by leveraging its proprietary genetic editing capabilities in site specific deletion, insertion and correction.
MGX-001, the Company’s lead, wholly-owned development program in hemophilia A, has demonstrated a preclinical profile with best-in-class treatment potential, including targeted genome editing and durable gene expression in a one-time treatment. MGX-001 is designed to provide curative, life-long protection from bleeding events and joint damage in adults and children, potentially enabling a new standard of care for the treatment of hemophilia A. The Company is also currently pursuing indications leveraging the MGX-001 site-specific genome integration system and partnered assets targeting cardiometabolic diseases. For more information, please visit https://metagenomi.co/.
Cautionary Note Regarding Forward‐Looking Statements
This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, each as amended. Such statements, which are often indicated by terms such as “anticipate,” “believe,” “could,” “estimate,” “expect,” “goal,” “intend,” “look forward to,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “will,” “would” and similar expressions include, but are not limited to, any statements relating to our product development programs, including the timing of and our ability to conduct IND-enabling studies and make regulatory filings such as INDs, expectations regarding MGX-001 including the preclinical profile with best-in-class treatment potential and timing to submit the IND/CTA package, statements regarding the Company’s plans to prioritize its preclinical pipeline and potential for value creation and sustainable growth, statements regarding upcoming milestones, statements concerning the potential of therapies and product candidates, statements concerning the impact of the organizational restructuring, statements concerning our
anticipated cash runway, and any other statements that are not historical facts. Forward-looking statements are based on management’s current expectations and are subject to risks and uncertainties that could negatively affect our business, operating results, financial condition, and stock value. Factors that could cause actual results to differ materially from those currently anticipated include: risks relating to our growth strategy; our ability to obtain, perform under, and maintain financing and strategic agreements and relationships; risks relating to the results of research and development activities; risks relating to the timing of IND submissions and starting and completing clinical trials; uncertainties relating to preclinical and clinical testing; our dependence on third party suppliers; our ability to attract, integrate and retain key personnel; the early stage of products under development; our need for substantial additional funds; government regulation and the current regulatory environment; patent and intellectual property matters; competition; the volatility of capital markets and other adverse macroeconomic factors; as well as other risks described in “Risk Factors,” in our most recent Form 10-K and other risk factors set forth from time to time in our filings with the Securities and Exchange Commission made pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934, as amended. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in our expectations or any changes in events, conditions or circumstances on which any such statement is based, except as required by law, and we claim the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995.
Investor Contact:
Brian Ritchie
LifeSci Advisors
BRitchie@lifesciadvisors.com
Condensed Financial Statements
Condensed Balance Sheet Data
(Unaudited)
|
|
June 30, |
|
|
December 31, |
|
||
(in thousands) |
|
2026 |
|
|
2025 |
|
||
Cash, cash equivalents and available-for-sale marketable securities |
|
$ |
120,664 |
|
|
$ |
160,799 |
|
Total assets |
|
$ |
173,701 |
|
|
$ |
221,103 |
|
Total liabilities |
|
$ |
61,134 |
|
|
$ |
62,507 |
|
Total stockholders’ equity |
|
$ |
112,567 |
|
|
$ |
158,596 |
|
Total liabilities and stockholders’ equity |
|
$ |
173,701 |
|
|
$ |
221,103 |
|
Condensed Statements of Operations
(Unaudited)
|
|
Three Months Ended |
|
|
Six Months Ended |
|
||||||||||
(In thousands, except share and per share data) |
|
2026 |
|
|
2025 |
|
|
2026 |
|
|
2025 |
|
||||
Collaboration revenue |
|
$ |
(257 |
) |
|
$ |
8,513 |
|
|
$ |
991 |
|
|
$ |
12,640 |
|
Operating expenses: |
|
|
|
|
|
|
|
|
|
|
|
|
||||
Research and development |
|
|
22,512 |
|
|
|
22,507 |
|
|
|
41,812 |
|
|
|
47,649 |
|
General and administrative |
|
|
6,004 |
|
|
|
6,993 |
|
|
|
12,539 |
|
|
|
13,798 |
|
Total operating expenses |
|
|
28,516 |
|
|
|
29,500 |
|
|
|
54,351 |
|
|
|
61,447 |
|
Loss from operations |
|
|
(28,773 |
) |
|
|
(20,987 |
) |
|
|
(53,360 |
) |
|
|
(48,807 |
) |
Other income (expense): |
|
|
|
|
|
|
|
|
|
|
|
|
||||
Interest income |
|
|
1,256 |
|
|
|
2,485 |
|
|
|
2,795 |
|
|
|
5,372 |
|
Change in fair value of long-term investments |
|
|
— |
|
|
|
(1,292 |
) |
|
|
— |
|
|
|
(1,292 |
) |
Other income (expense), net |
|
|
35 |
|
|
|
(70 |
) |
|
|
34 |
|
|
|
(78 |
) |
Total other income, net |
|
|
1,291 |
|
|
|
1,123 |
|
|
|
2,829 |
|
|
|
4,002 |
|
Net loss before provision for income taxes |
|
|
(27,482 |
) |
|
|
(19,864 |
) |
|
|
(50,531 |
) |
|
|
(44,805 |
) |
Provision for income taxes |
|
|
— |
|
|
|
(44 |
) |
|
|
(10 |
) |
|
|
(142 |
) |
Net loss |
|
$ |
(27,482 |
) |
|
$ |
(19,908 |
) |
|
$ |
(50,541 |
) |
|
$ |
(44,947 |
) |
Net loss per share attributable to common stockholders, basic and diluted |
|
$ |
(0.73 |
) |
|
$ |
(0.54 |
) |
|
$ |
(1.34 |
) |
|
$ |
(1.21 |
) |
Weighted average common shares outstanding, basic and diluted |
|
|
37,658,250 |
|
|
|
37,156,979 |
|
|
|
37,619,885 |
|
|
|
37,088,383 |
|